Clinical Trial Detail

NCT ID NCT03993873
Title Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Turning Point Therapeutics, Inc.
Indications

lung non-small cell carcinoma

stomach cancer

gastroesophageal junction adenocarcinoma

hepatocellular carcinoma

Advanced Solid Tumor

Therapies

TPX-0022

Age Groups: adult senior

Additional content available in CKB BOOST